MOLECULAR MECHANISM AND THERAPEUTIC VULNERABILITIES IN TRIPLE-NEGATIVE BREAST CANCER

Read full text Summarise with VIRAT
Authors: Laiba Jamil, Saira Ali, Aiza Jamil, Hajra Azam, Sadaf Shahid, Wisha Arshad, Maimoona Mukhtar, Saher Noor, Ali Sabir
Cited by: 0
References: 98

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subtype of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (HER2) expression. Due to the lack of these therapeutic targets, TNBC has historically been associated with limited treatment options and poorer clinical outcomes compared with other breast cancer subtypes. In recent years, advances in molecular biology and cancer genomics have significantly improved the understanding of TNBC pathogenesis, leading to the development of novel targeted and immune-based therapeutic strategies. This review summarizes the current knowledge regarding the molecular characteristics, biological heterogeneity, and clinical challenges associated with TNBC. In addition, the article discusses emerging therapeutic approaches, including poly (ADP-ribose) polymerase (PARP) inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, androgen receptor-targeted therapies, metabolic pathway inhibitors, and epigenetic therapies. The role of precision medicine, biomarker discovery, and advanced technologies such as artificial intelligence in improving diagnosis and treatment selection is also highlighted. Furthermore, the review examines ongoing research efforts aimed at overcoming treatment resistance and improving long-term clinical outcomes in TNBC patients. Understanding the complex molecular landscape of TNBC is essential for the development of more effective and personalized therapeutic strategies. Continued progress in translational research, biomarker identification, and clinical trials is expected to significantly improve prognosis and quality of life for patients affected by this challenging breast cancer subtype.

Fields of Study & Subjects

Breast Cancer Treatment Studies PARP inhibition in cancer therapy Breast Lesions and Carcinomas

Publication details

Journal / source
Journal of medical & health sciences review.
Volume
3
Issue
1
Pages
644–664
Publication date
26 March 2026
Language
EN